Mounjaro (Tirzepatide): The GLP-1 Pathway, Approvals, and Genetics

Part of the PlexusDx Education Hub, your evidence-based resource on GLP-1 therapies, weight protocols, and the genetics that shape metabolic decisions. Browse all Peptides & GLP-1 education

Mounjaro is the brand; tirzepatide is the molecule. To understand the drug is to understand the GLP-1 pathway it acts on. This article traces GLP-1 from natural hormone to receptor-agonist drug class, names the FDA-approved compounds as of April 2026, and closes on the genetic terrain every one of them works within.

GLP-1, the hormone before the drug

Native GLP-1 (glucagon-like peptide-1) is a 30- to 31-amino-acid incretin peptide secreted by intestinal L-cells after eating. It triggers glucose-dependent insulin release from pancreatic beta cells, suppresses glucagon, slows gastric emptying, and activates hypothalamic satiety circuits. Its natural half-life is only about two minutes because the enzyme dipeptidyl peptidase-4 (DPP-4) degrades it almost immediately. That glucose-dependent quality matters: because native GLP-1 stimulates insulin mainly when blood sugar is elevated, the hormone modulates rather than overrides normal glucose control, which is part of why the pathway became such an attractive pharmacological target.

Turning a two-minute hormone into a weekly drug

GLP-1 receptor agonist medications are engineered to resist DPP-4, stretching half-life from minutes into days or weeks. They bind the same GLP-1 receptor as the native hormone and reproduce its downstream effects on insulin secretion, glucagon suppression, gastric emptying, and satiety. Tirzepatide-based compounds add agonism at the GIP receptor, a related incretin target, and that dual action is one of the class's defining molecular distinctions as of April 2026.

The FDA-approved lineup as of April 2026

The approved GLP-1 receptor agonist class includes exenatide (Byetta, 2005; Bydureon), liraglutide (Victoza, 2010; Saxenda, 2014), dulaglutide (Trulicity, 2014), semaglutide (Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021), and tirzepatide (Mounjaro, 2022; Zepbound, 2023; Zepbound expanded to OSA, 2024). The chronology tracks a clear trajectory: early agents required daily or twice-daily injection, while later molecules were engineered for once-weekly dosing and progressively larger effects on glucose and weight. Investigational, not FDA-approved, compounds in late-stage development include retatrutide, a GIP/GLP-1/glucagon triple agonist, and orforglipron, an oral non-peptide small-molecule GLP-1 receptor agonist. As investigational agents, these are not sold by PlexusDx and carry no dosing or usage guidance here; they are named only to sketch where the class may be heading.

The genetic terrain beneath the pathway

Because these drugs act on a receptor pathway that carries natural human variation, genetics sets the backdrop. GLP1R, the GLP-1 receptor gene itself, is the most direct variable, with variants influencing receptor density and incretin signaling efficiency. FTO shapes appetite regulation and adiposity set-point, MC4R governs hypothalamic satiety and total intake, and TCF7L2 affects insulin secretion and incretin response. These are pathway-level variants: they do not predict response to any single compound, but they map the metabolic ground each compound must act on. Two people prescribed the same tirzepatide protocol can carry very different versions of these genes, which is one reason clinical outcomes vary so widely from person to person.

PlexusDx offers tirzepatide through its Weight Management Protocols, including the Tirzepatide protocol. The differentiator is starting with that terrain rather than ignoring it: the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2 variants that describe your baseline GLP-1, appetite, and energy-balance biology, turning a pathway you cannot see into context you can discuss with a provider.

Related reading on PlexusDx: Weight Loss Injections Mounjaro, Cost of Mounjaro, Mounjaro Injection Sites, Mounjaro Cost with Insurance.

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Explore the PlexusDx Weight Management Protocols collection, or begin upstream with the genetics and take the Precision Peptide Genetic Test first.

Frequently Asked Questions

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1, an incretin hormone released by intestinal L-cells in response to food. It prompts glucose-dependent insulin release, slows gastric emptying, and signals satiety to the brain. The GLP-1 receptor agonist drug class, tirzepatide among them, is engineered to reproduce those hormonal effects for far longer.

How is tirzepatide different from a single GLP-1 agonist?

Tirzepatide is a dual agonist: it engages the GLP-1 receptor and, additionally, the GIP receptor, a second incretin target. Single-agonist compounds such as semaglutide act on the GLP-1 receptor alone. That extra GIP action is one of the key molecular distinctions in the class as of April 2026.

How are these medications administered?

Most FDA-approved GLP-1 receptor agonists are given as subcutaneous injections, weekly or daily depending on the compound. Rybelsus is the only FDA-approved oral option as of April 2026. Compounded oral GLP-1 protocols exist through licensed compounding pharmacy pathways and are not FDA-approved as branded products.

Does a genetic test tell me which GLP-1 to take?

No. The Precision Peptide Genetic Test does not predict which GLP-1 medication suits any individual. It analyzes pathway-level variants in FTO and MC4R, and other genes that shape baseline GLP-1 biology, providing context for a broader protocol conversation with a healthcare provider rather than a prescription.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education